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Abstract: Conventional immunoassays offer selective and quantitative detection of a number of
biomarkers, but are laborious and time-consuming. Magnetic particle-based assays allow easy and
rapid selection of analytes, but still suffer from the requirement of tedious multiple reaction and
washing steps. Here, we demonstrate the trapping of functionalised magnetic particles within a
microchannel for performing rapid immunoassays by flushing consecutive reagent and washing
solutions over the trapped particle plug. Three main studies were performed to investigate the
potential of the platform for quantitative analysis of biomarkers: (i) a streptavidin-biotin binding
assay; (ii) a sandwich assay of the inflammation biomarker, C-reactive protein (CRP); and (iii)
detection of the steroid hormone, progesterone (P4), towards a competitive assay. Quantitative
analysis with low limits of detection was demonstrated with streptavidin-biotin, while the CRP and
P4 assays exhibited the ability to detect clinically relevant analytes, and all assays were completed in
only 15 min. These preliminary results show the great potential of the platform for performing rapid,
low volume magnetic particle plug-based assays of a range of clinical biomarkers via an exceedingly
simple technique.
Keywords: C-reactive protein (CRP); progesterone (P4); immunoassays; magnetic particles;
magnetism; microfluidics; particle trapping
1. Introduction
Enzyme-linked immunosorbent assays (ELISA) are a powerful method of identification and
quantification, utilising the specificity of labelled antibodies for their complementary antigens to
give a signal (e.g., via fluorescence or chemiluminescence) dependent on the concentration of the
latter [1,2]. However, while ELISA offers extremely low limits of detection and selectivity, the
process is exceedingly slow, requiring multiple reagent and washing steps that are both laborious
and time-consuming. The use of magnetic microparticles as solid supports has become incredibly
popular for immunoassays and other applications thanks to their high surface-to-volume ratios, small
sizes (0.1–100 µm), the range of functional groups that can be attached to the surfaces (e.g., antibodies,
DNA, and chemical groups), and the ability to easily manipulate the particles via an applied magnetic
field [3,4]. By employing antibody functionalised magnetic particles, immunoassay time frames can
be greatly reduced, with permanent magnets used to enable the separation of antigens from the
sample and speeding up the exchange of reaction and washing solutions. Even so, these magnetic
particle-based assays still require multiple manual solution changes; hence, despite being faster than
conventional ELISAs, they are still somewhat slow and require relatively large volumes of solutions.
The application of microfluidic devices [5–7], having channel networks with typical dimensions
on the order of 1–100 s of micrometres, provides a number of advantages to immunoassays by
reducing diffusion distances, reaction and washing time frames, as well as sample and reagent
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volumes [8–12]. Integration of magnetic particles with microfluidics thus combines the benefits of
both [13–16], and has yielded great success for on-chip bioanalysis [12,16]. One of the easiest methods
of performing techniques such as immunoassays is via the trapping of functionalised microparticles
within the microchannel [17,18], before pumping solutions of sample, washing buffer and reagents
over the particles. Trapping magnetic particles within a microchannel can easily be achieved by
simply applying an external magnetic field that can be generated via a number of sources, including
permanent magnets [19–32], integrated microelectromagnets [33–38], electromagnets [39–43], and
externally magnetisable integrated microstructures [44–49].
Most often, this type of setup is used for the separation of target analytes from a sample;
as the sample is pumped over the trapped magnetic particles the analytes bind to the functional
groups on the particles, after which the particles are washed with buffer solution [13]. However,
immunoassays are performed by consecutively flushing sample, reagent and washing solutions
over antibody-coated particles, thereby enabling selection of a target analyte from a sample and
its subsequent labelling (e.g., with a fluorescent tag) for detection. Such processes have been
applied to assays for streptavidin-biotin [38,50], protein A [31,50], mouse IgG [26,29,51], parathyroid
hormone [52], interleukin-5 [52], bovine serum albumin (BSA) [42], alkaline phosphatase [53], and
glycine [50]. Modifications to this methodology have included the use of segmented flow, in which
the consecutive reaction and washing solutions are contained within droplets that are pumped over
the trapped particles [53], and the generation of a fluidised bed of magnetic particles to enhance
mixing [29]. However, while modifications such as these can yield low detection limits with small
sample volumes, it often comes at the cost of greater complexity. Further applications beyond
immunoassays have included RNA isolation [54,55], DNA hybridisation [56–58] and separation [59],
purification of polymerase chain reaction (PCR) products for gene synthesis [60], cell capture for DNA
detection [61,62], reaction rate measurements [63], protein digestion [28,64–66], and the electrochemical
detection of peroxide [48], among others.
Previously, we have demonstrated the trapping of plugs of magnetic particles in microchannels
for performing simultaneous assays on particles featuring different surface functionalities [50].
In order to maintain a simple setup and user-friendliness, the apparatus consists only of a capillary
placed between two permanent magnets and connected to a single syringe pump operating in
withdrawal mode. Functionalised magnetic particles are first pumped into the microchannel and
trapped between the magnets, creating a particle plug that is consecutively exposed to reagent and
washing solutions prior to detection of the target analyte using fluorescence (Figure 1). By placing
multiple pairs of magnets upstream of each other, three different particle plugs (featuring glycine,
protein A, and streptavidin surface groups) were generated for the simultaneous assays. We have also
demonstrated how diamagnetic repulsion forces can be employed for performing particle plug-based
assays [67,68]. The proof-of-principle work thus far has involved only qualitative assays to test the
platform. Here, we investigate the potential for using this simple platform for quantitative analysis
towards its application in clinical diagnostics. Three main approaches are described here: (i) the
ability to generate a calibration curve and obtain a limit of detection for a streptavidin-biotin binding
assay; (ii) the detection in a relevant concentration range of an inflammation and infection biomarker,
C-reactive protein (CRP), via a sandwich immunoassay; and (iii) the detection of a clinically relevant
steroid hormone, progesterone (P4), at multiple concentrations with a view to competitive assays.
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Figure 1. Principle of magnetic particle plug-based assays: (a) functionalised magnetic particles are 
introduced into a microchannel and trapped between two magnets, forming a plug; (b) a fluorescently 
labelled reagent or sample solution is flushed over the particle plug, with the reagent or target analyte 
Figure 1. Principle of magnetic particle plug-based assays: (a) functionalised magnetic particles are
introduced into a microchannel and trapped between two magnets, forming a plug; (b) a fluorescently
labelled reagent or sample solution is flushed over the particle plug, with the reagent or target analyte
binding to the particles; and (c) the microchannel is washed with buffer solution, allowing fluorescence
detection of the trapped particle plug.
2. Materials and Methods
2.1. Reagents and Particles
Tris(hydroxymethyl)aminomethane (Tris), 2-(N-morpholino)ethanesulfonic acid (MES),
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide
(NHS), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (Dorset, UK).
Superparamagnetic particles with a 2.8 µm diameter were purchased from Invitrogen (Paisley,
UK) with two different surface functionalities: streptavidin (Dynabeads M-270 Streptavidin) and
carboxylic acid (Dynabeads M-270 Carboxylic Acid). Biotin-4-fluorescein (λex = 494 nm, λem = 524 nm)
and phosphate buffered saline (PBS) tablets were also purchased from Invitrogen.
Recombinant human C-reactive protein (CRP) and primary CRP antibody (1˝ anti-CRP;
biotinylated mouse anti-human C-reactive protein) were purchased from R&D Systems (Abington,
UK). Secondary CRP antibody tagged with a fluorescent label (2˝ anti-CRP-FITC; polyclonal goat
anti-human C-reactive protein conjugated to fluorescein isothiocyanate, λex = 495 nm, λem = 521 nm)
was purchased from Abcam (Cambridge, UK) in PBS solution at a stock concentration of 1 mg¨mL´1.
Progesterone labelled with fluorescein isothiocyanate (P4-FITC, 1 mg¨mL´1 stock solution) and
progesterone antibody (anti-P4) were purchased from R&D Systems.
2.2. Preparation of Solutions
All solutions were prepared in double-filtered (0.05 µm) high purity water (18.2 MΩ¨ cm at 25 ˝C)
via an ELGA Option 4 system that fed into an ELGA UHG PS system, both of which were from ELGA
Process Water (Marlow, UK).
PBS solution (pH 7.45) was prepared by dissolving a tablet in 1000 mL water, and had BSA added
to a concentration of 0.01% w/v in order to reduce non-specific binding of reagents and the sticking of
magnetic particles to the capillary walls or to each other. Tris buffer (20 mM, pH 8) was prepared by
dissolving tris(hydroxymethyl)aminomethane in water, with 0.1% w/v BSA added. MES buffer (pH 5)
was prepared to a concentration of 25 mM in water.
Fluorescently labelled biotin (biotin-4-fluorescein) was dissolved in PBS solution to a stock
concentration of 1 mg¨mL´1 and protected from light by wrapping the container in aluminium
foil. CRP antigen was reconstituted in Tris buffer to a concentration of 200 µg¨mL´1, as per the
manufacturer’s instructions, then diluted in PBS solution to concentrations of 1 µg¨mL´1 and
10 µg¨mL´1. Primary CRP antibody (1˝ anti-CRP) was reconstituted in PBS solution to a concentration
of 50 µg¨mL´1, as per the manufacturer’s instructions, and then further diluted in PBS to 1 µg¨mL´1.
Secondary CRP antibody (2˝ anti-CRP-FITC) was diluted in PBS to a concentration of 100 µg¨mL´1.
Progesterone antibody (anti-P4) was dissolved in MES buffer (25 mM, pH 5) to a concentration
of 1 µg¨mL´1, while fluorescently labelled progesterone (P4-FITC) was diluted in PBS solution to
concentrations of 0.1–100 µg¨mL´1.
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2.3. Preparation of Anti-CRP Functionalised Magnetic Particles
Immobilisation of biotinylated primary CRP antibodies (1˝ anti-CRP) onto streptavidin
functionalised magnetic particles (Dynabeads M-270 Streptavidin) was achieved via the
streptavidin-biotin interaction, as previously reported [69,70]. Briefly, 10 µL of stock particle suspension
(6.5 ˆ 108 particles¨mL´1) was added to a 1.5 mL microcentrifuge tube (VWR, Leicester, UK), followed
by 200 µL of 1˝ anti-CRP solution at a concentration of 10 µg¨mL´1, and incubated for 15 min with
slow tilt rotation in order for the biotinylated antibodies to bind to the streptavidin-coated particles.
The particles were then washed three times using the following procedure.
The particles were pulled to the side of the tube via an external magnet and the supernatant
removed using a pipette. PBS solution (1000 µL) was added to the tube, which was vortexed for 20 s
to resuspend the particles. This washing process was repeated twice more, and the particles finally
resuspended in PBS buffer solution.
2.4. Preparation of Anti-P4 Functionalised Magnetic Particles
Immobilisation of progesterone antibody (anti-P4) onto carboxylic acid functionalised magnetic
particles (Dynabeads M-270 Carboxylic Acid) was achieved via amide bond formation between the
carboxylic acid groups of the particles and the primary amine groups of the antibodies. The procedure
was performed as per the manufacturer’s instructions for a two-step coating procedure [71].
The first step of the process involved the “activation” of the magnetic particles with a carbodiimide
(EDC) and N-hydroxysuccinimide (NHS). One hundred microlitres of stock particle suspension
(2 ˆ 109 particles¨mL´1) was added to a microcentrifuge tube and washed twice, as described
previously, with 100 µL of MES buffer (25 mM, pH 5). Immediately prior to use, a 50 mg¨mL´1
solution of EDC was prepared in cold MES buffer, while a 50 mg¨mL´1 solution of NHS was also
prepared in MES buffer. The supernatant of the particle suspension was removed, and 50 µL of EDC
solution and 50 µL of NHS solution were added to the magnetic particles. The suspension was mixed
via a vortexer and allowed to incubate with slow tilt rotation at room temperature for 30 min.
Following incubation, the particles were washed twice with 100 µL of MES buffer. The supernatant
was removed, and 60 µL of anti-P4 (1 µg¨mL´1) in MES buffer was added, followed by a further 40 µL
of MES buffer. The mixture was incubated for 2 h at 20 ˝C, then the particles were washed four times
with PBS solution (pH 7.45) and finally resuspended in PBS solution.
2.5. Instrumental Setup
Two rectangular neodymium-iron-boron (NdFeB) magnets (4 ˆ 4 ˆ 6 mm3, Magnet Sales,
Swindon, UK) were glued onto a glass microscope slide (6 ˆ 2.5 cm2) using Araldite Rapid epoxy
resin (RS Components, Northants, UK), such that their opposing poles were facing and there was a
1 mm gap between them. A 10 cm long piece of fused silica capillary (150 µm ID (Inner Diameter),
363 µm OD (Outer Diameter), CM Scientific, Silsden, UK) had a section of its polyimide coating burned
away with a lighter and wiped with a soft tissue to create a region for visualisation of trapped particles.
The capillary was then placed between the pair of magnets (Figure 2a) and held in place using Blu-Tack
(Bostick, UK). The two ends of the capillary were connected to Tygon tubing (254 µm ID, 762 µm OD,
Cole-Parmer, London, UK), with one piece of tubing interfaced to a syringe on a syringe pump (PHD
22/2000, Harvard Apparatus, Kent, UK) and the other piece of tubing dipped into a microcentrifuge
tube, acting as a reservoir, containing sample or buffer solution.
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Figure 2. Setup of the microfluidic device: (a) photograph of a fused silica capillary located in the
1 mm gap between two 4 ˆ 4 ˆ 6 mm3 NdFeB magnets that were fixed to a glass microscope slide; and
(b) photograph of the glass microscope slide, holding the capillary and magnets, on the sample stage
of an inverted fluorescence microscope. Samples, reagents and buffer solutions were introduced into
the capillary from reservoirs via a syringe pump in withdrawal mode.
Solutions were drawn through the capillary from the sample/buffer reservoir via negative
pressure from the syringe pump operating in withdrawal mode. The glass slide holding the magnets
and capillary setup was situated on the sample stage of an inverted fluorescence microscope (TE-2000U,
Nikon, Surrey, UK) (Figure 2b). Images were captured via a cooled CCD (charge-coupled device)
camera (QImaging Retiga-EXL, Media Cybernetics, Buckinghamshire, UK) and Image-Pro Plus 6
software (Media Cybernetics, Buckinghamshire, UK). Such images were analysed using ImageJ
software (US National Institutes of Health, Bethesda, MD, USA).
2.6. Experimental Procedures
2.6.1. Capillary-Based Particle Trapping and Reactions
Prior to performing an experiment, the capillary was cleaned and pre-treated by flushing
consecutively with ethanol, water and PBS solution. Following this, the inlet tubing connected
to the capillary was dipped into a suspension of magnetic particles in a microcentrifuge tube and
negative pressure applied via the syringe pump to draw the particle suspension through the capillary.
After a certain time frame, the syringe pump was stopped and the flow allowed to come to a halt
(~30 s in order to prevent air from entering the system during solution exchange) before the inlet
tubing was removed from the particle suspension vial and placed into a vial of PBS solution. PBS was
then drawn through the capillary for several minutes to ensure that all particles within the capillary
would reach the region between the two magnets to form a plug of particles. Characterisation of the
particle plugs was performed at this stage by taking photographs via the microscope and CCD camera,
and analysing the images with ImageJ software to determine the area of the plugs.
To perform a reaction on the particle plug, once the particle suspension had been introduced into
the capillary, the microcentrifuge tube was exchanged for one containing a reagent solution, which
was pumped through the capillary for several minutes such that it was allowed to wash over the
particle plug, before the pump was again stopped. When the flow had stopped, the inlet tubing was
placed in a vial of PBS solution, which was pumped over the particle plug to wash away any unbound
material. The CRP assay, being a two-step sandwich assay, required a second reaction following the
first. Finally, fluorescence images were taken of the particle plug and the fluorescence intensity of
the plugs measured via ImageJ. Analysis was performed manually by drawing a small box inside the
image of the particle plug, determining the maximum greyscale value (as a measure of fluorescence
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intensity), and deducting an average background intensity. This process was repeated for several
regions inside the particle plug to provide average of the maximum fluorescence intensities.
2.6.2. Formation and Characterisation of Magnetic Particle Plugs
Prior to performing reactions, the formation of the particle plugs was characterised based on the
applied flow rate and the particle concentration. A suspension of Dynabeads M-270 Carboxylic Acid
particles in PBS buffer was pumped into the capillary for 90 s, then the solution swapped to PBS which
was pumped through the capillary for a further 10 min. Images of the forming particle plug were
collected every minute and experiments were repeated three times. Flow rates of 180–300 µL¨h´1
(equivalent to linear velocities of 2.8–4.7 mm¨ s´1) and particle concentrations of 1 ˆ 106 to 2 ˆ 107
particles¨mL´1 were studied.
2.6.3. Streptavidin-Biotin Assay
In order to test and optimise reactions on the setup, a streptavidin-biotin binding assay was
investigated. Streptavidin functionalised magnetic particles (Dynabeads M-270 Streptavidin) in PBS
solution (1 ˆ 107 particles¨mL´1) were pumped through the capillary for 2 min at a flow rate of
300 µL¨h´1 (4.7 mm¨ s´1) to form a particle plug between the NdFeB magnets. The particle suspension
vial was exchanged for one containing biotin-4-fluorescein solution, which was flushed over the
trapped particle plug at 300 µL¨h´1 for 3 min, then the sample vial was exchanged again for PBS
solution. The PBS solution was drawn through the capillary for 3 min at 300 µL¨h´1 to wash the particle
plug, whose fluorescence intensity was then measured. The concentration of biotin-4-fluorescein was
varied between 0.1–5 µg¨mL´1. The effect of exposure time during the capture of fluorescence images
was also studied using the streptavidin-biotin reaction for optimisation.
2.6.4. C-Reactive Protein (CRP) Assay
Magnetic particles featuring surface-bound primary CRP antibodies (1˝ anti-CRP), prepared
as described in Section 2.3, in PBS solution (1 ˆ 107 particles¨mL´1) were introduced into the
capillary at a flow rate of 300 µL¨h´1 (4.7 mm¨ s´1) for 2 min in order to form the particle plug
between the two magnets. The particle suspension tube was replaced with a tube containing CRP
solution (1 or 10 µg¨mL´1), which was pumped over the particle plug for 3 min at the same flow rate.
Fluorescently tagged secondary antibody (2˝ anti-CRP-FITC) solution (100 µg¨mL´1) was then flushed
over the particle plug for 3 min at 300 µL¨h´1, and the plug was finally washed with PBS solution for
5 min prior to fluorescence measurement of the particles.
2.6.5. Progesterone (P4) Assay
Magnetic particles functionalised with progesterone antibody (anti-P4), prepared as described
in Section 2.4, in PBS solution (1 ˆ 107 particles¨mL´1) were pumped into the capillary at a flow
rate of 300 µL¨h´1 (4.7 mm¨ s´1) for 2 min for plug formation between the magnets. A solution of
fluorescently labelled progesterone (P4-FITC), whose concentration was varied from 0.1–100 µg¨mL´1,
was subsequently flushed over the trapped plug at 300 µL¨h´1 for 3 min, before washing the plug with
PBS solution for 3 min to remove any unbound P4-FITC. Fluorescence analysis was then performed on
the trapped magnetic particle plug.
3. Results and Discussion
3.1. Formation and Characterisation of Magnetic Particle Plugs
When particle suspensions were introduced into the fused silica capillary via negative pressure,
they flowed freely through the tube until they approached the two magnets. At this point, they became
trapped in the field between the magnets and began to form a plug of particles that grew larger as
particles continued to be introduced into the 150 µm ID capillary. The particles remained stationary
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as they were trapped in the field, as opposed to the continuously recirculating plugs observed when
diamagnetic particles are trapped in a magnetic fluid [67,68]. The location of particle plug formation
was x « 1.7 mm from the centre (x = 0 mm) of the magnets (Figure 3a). In order to investigate this
further, the magnetic field was modelled in FEMM 4.2 software (Figure 3b). The resultant simulations
showed that the region of highest magnetic flux density (vectors not shown) was located between
x « ´1.5 mm and x « 1.5 mm (Figure 3c), hence the location of particle trapping was as predicted.Micromachines 2016, 7, 77 7 of 17 
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As stated above, the particles were able to flow freely through the capillary. No evidence of
sedimentation due to gravity was observed, with the theoretical forces on the particles due to gravity
being calculated as 68 femtonewtons (fN), yielding a sedimentation velocity of 2.6 µm¨ s´1. This value
was negligible compared to the minimal linear flow rate of 2.8 mm¨ s´1 (at a volumetric flow rate of
180 µL¨h´1) in the capillary. Furthermore, inertial lift forces may also have helped to prevent particles
from settling against the capillary wall while in flow. These observations also supported those from
our previous work [50,67,68]. The sticking of particles to the capillary walls was minimal, with BSA
added to solutions to prevent this from occurring, and was found not to interfere with experiments.
Prior to performing assays on trapped particles, two parameters affecting plug formation were
investigated, namely the applied flow rate and the particle concentration, towards optimisation in
terms of rapid formation of a plug deemed large enough for yielding suitable fluorescence signals.
Carboxylic acid functionalised magnetic particles (2.8 µm) in PBS solution (pH 7.45) were e ployed
for these tests.
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3.1.1. Effect of Flow Rate
The applied flow rate is an important parameter since high flow rates would allow the collection
of more particles in the trap in a shorter period of time. However, too high a flow rate could lead to
particles escaping the trap when the hydrodynamic forces dominate the magnetic forces. Here, particle
suspension (1 ˆ 106 particles¨mL´1) was introduced into the capillary at a flow rate of 5 µL¨min´1
for 90 s. The sample vial was then exchanged for one containing PBS solution, which was pumped
through the capillary at flow rates of 180, 240 and 300 µL¨h´1 (equivalent to linear velocities of 2.8, 3.8
and 4.7 mm¨ s´1, respectively) in order to determine the effect of flow rate on plug formation. Images
of the plugs were captured every minute for 10 min.
The build-up of the particle plugs can be seen in Figure 4a–c, which shows the size of the plugs
at time frames of 1 min, 5 min, and 10 min after initialising the flow. The total area occupied by a
particle plug (units of pixels2, with one square pixel comprising approximately 5.6 µm2) was measured
using ImageJ and the results are plotted in Figure 4d, which clearly demonstrates that faster flow rates
yielded larger plugs of trapped particles. Interestingly, however, it appeared that following the first
minute of trapping, the plugs actually grew at similar rates at each of the three flow rates. This may
have been due to the build-up of the plugs in three dimensions within the capillary while only a 2D
image could be taken for analysis, a parameter that could be explored in future work. Importantly,
even at the highest flow rate tested of 300 µL¨h´1 (4.7 mm¨ s´1), 100% trapping efficiency was achieved.
Hence, this flow rate was employed in all subsequent experiments to yield the rapid formation of large
plugs with no loss of particles.Micromachines 2016, 7, 77 8 of 17 
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Figure 4. The effect of flow rate on magnetic particle plug formation. (a–c) Photographs of plug
formation at time points of 1, 5 and 10 min for flow rates of: (a) 180 µL¨h´1; (b) 240 µL¨h´1; and (c)
300 µL¨h´1. (d) Plot of measured plug sizes over time at the three different flow rates. Each pixel was
approximately equivalent to an area of 5.6 µm2.
3.1.2. Effect of Particle Concentration
The effect of particle concentration on plug formation was investigated by pumping the magnetic
particles through the capillary at concentrations of 5 ˆ 106, 1 ˆ 107 and 2 ˆ 107 particles¨mL´1 for 90 s
at 300 µL¨h´1. PBS solution was then flushed through the capillary for 10 min at the same flow rate,
with photographs taken of the growing particle plug every minute.
Images of the trapped particle plugs for each concentration can be seen in Figure 5a–c at 1, 5 and
10 min after starting the washing step. As expected, higher particle concentrations yielded larger plugs
in shorter times. The total area of each plug was analysed using ImageJ software and the results are
plotted in Figure 5d. Again, the rates of plug formation were actually largely quite similar in each case
(from a 2D viewpoint at least), but nonetheless reaffirmed that the higher the particle concentration
was, the larger the plug that was formed within a certain time frame. However, the plug formed
at higher concentrations was a lot more spread out across the capillary (in the x-direction), hence a
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concentration of 1 ˆ 107 particles¨mL´1 was employed for subsequent experiments in order to form a
fairly large plug with a better defined shape.
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3.2. Streptavidin-Biotin Assay
In order to test the setup for performing reactions on particle plugs, proof-of-principle assays
based on the streptavidin-biotin interaction were performed. While we have previously demonstrated
a streptavidin-biotin binding ssa on a magnetic p rticle plug [50], he tests were only qualitative.
Here, we investigated the ability to produce calibration curves of biotin concentrations using the
magnetic trapping platform.
Dynabeads M-270 Streptavidin particles (1 ˆ 107 particles¨mL´1) were pumped into the
capillary at a flow rate of 300 µL¨h´1 for 2 min to generate the particle plug between the magnets.
This was followed by a solution of biotin-4-fluorescein at 300 µL¨h´1 for 3 min, and finally a
solution of PBS for 3 min in order to wash the particle plug. A range of biotin-4-fluorescein
concentrations (0.1–5 µg¨mL´1) were tested, and photographs of particle plugs exposed to each of
these concentrations are shown in Figure 6a–e. Clearly, as the concentration of biotin was increased
the fluorescence intensity of the particle plug also increased, indicating successful binding of the
fluorescent biotin to the streptavidin-coated particles.
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Figure 6. Streptavidin-biotin assays performed by flushing a solution of fluorescently labelled biotin
over a trapped plug of streptavidin functionalised magnetic particles. (a) Bright-field image of the
trapped particle plug. (b–e) Fluorescence images of streptavidin particle plugs exposed to varying
concentrations of biotin: (b) 0.1 µg¨mL´1; (c) 0.5 µg¨mL´1; (d) 1 µg¨mL´1; and (e) 5 µg¨mL´1.
(f) Cali ration graph of p rticle plug fluorescence intensities exposed to a range of fluorescently
labelled biotin concentrations.
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In order to optimise the platform further for quantitative analysis, the effect of CCD camera
exposure time was investigated alongside the ability to generate calibration curves. Multiple
concentrations of biotin (0.1–5 µg¨mL´1) were flushed over particle plugs and analysed using a
range of CCD camera exposure times (0.1–0.6 s). The resultant plots are shown in Figure S1a and
demonstrate typical dose–response curves, with the fluorescence intensity first increasing sharply
as the biotin concentration increased before reaching a plateau at ~2 µg¨mL´1 as the number of
streptavidin binding sites on the particles diminished. The polystyrene matrix of the magnetic particles
exhibited auto-fluorescence, hence the non-zero fluorescence intensity even in the absence of biotin.
Due to the plateau above 2 µg¨mL´1, the curves were re-plotted to show the linear responses between
0.1–2 µg¨mL´1 (Figure S1b), demonstrating the suitability of the platform for quantitative analysis.
Clearly, as the CCD camera exposure time was increased the measured fluorescence intensities
also increased, as expected since more of the fluorescence light was allowed to enter the CCD. However,
while higher exposure times yielded greater intensities, they also exhibited poorer coefficients
of determination (R2) as demonstrated in Figure S1b. Based on this, the results obtained with
the 0.3 s exposure time were selected as being the optimum, with the calibration curve (Figure 6f)
yielding a limit of detection (LOD) of 40 ng¨mL´1 and a limit of quantification (LOQ) of 134 ng¨mL´1
for fluorescently labelled biotin.
These results demonstrated the potential of the platform for quantitative analysis with low
limits of detection in a fast time frame (<10 min), while consuming only 15 µL of sample/reagent.
Furthermore, some aspects could be optimised further, such as the reaction times, which would lead
to shorter procedural times and lower reagent consumption, and the washing times. The detection
method could also be improved to increase the coefficient of determination while reducing the limits of
detection further. While these will be investigated further in later studies, the promising initial results
prompted further studies with more clinically relevant biomarkers towards the use of the platform as
a diagnostic tool.
3.3. C-Reactive Protein (CRP) Assay
The first clinically relevant biomarker tested using the magnetic plug platform was C-reactive
protein (CRP) [72–75]. CRP is an acute phase reactant present in blood whose levels increase
dramatically, up to 1000-fold, in response to inflammation, cell damage or tissue injury, hence its
monitoring in a clinical setting for infections and inflammation. Normal levels of CRP in serum are
considered to be 1–10 µg¨mL´1, with levels of 10–40 µg¨mL´1 suggesting viral infection or mild
inflammation while levels of 40–200 µg¨mL´1 indicate active inflammation or bacterial infection.
Chronic minor elevations in CRP levels may also be an indicator for cardiovascular disease (CVD),
hence so-called high-sensitivity CRP (hs-CRP) testing is performed to monitor levels over time
(<1µg¨mL´1 = low CVD risk; 1–3 µg¨mL´1 = medium risk, >3 µg¨mL´1 = high risk) [76–78]. Due to its
clinical relevance and the detection levels required, CRP was deemed to be an excellent choice for
testing the ability to perform sandwich enzyme-linked immunosorbent (ELISA) assays using the
magnetic particle plug platform.
Magnetic particles functionalised with 1˝ anti-CRP (1 ˆ 107 particles¨mL´1) were introduced into
the capillary at 300 µL¨h´1 for 2 min for magnetic particle plug formation. This was followed by a
solution of CRP for 3 min, allowing the CRP analyte to bind to the antibody-coated particles, before
being flushed with a solution of 2˝ anti-FITC (100 µg¨mL´1) for 3 min that fluorescently labelled
the captured CRP analyte. Finally, the particle plug was washed with PBS solution for 5 min and
fluorescence images recorded for analysis.
Fluorescence images of particle plugs are shown in Figure 7a–c. Figure 7a demonstrates the
auto-fluorescence of the particles prior to a reaction being performed, while Figure 7b,c show the
effects of exposure to CRP concentrations of 1 µg¨mL´1 and 10 µg¨mL´1, respectively, followed
by reaction with the 2˝ anti-CRP-FITC (100 µg¨mL´1). The photographs clearly show an increase
in fluorescence intensity with increasing CRP concentration, and the fluorescence intensity of the
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particle plugs are plotted in Figure 7d. While a full range of CRP standards was not tested, it is
nonetheless clear that clinically relevant concentrations of CRP (>10 µg¨mL´1 for inflammation and
infection; 1–10 µg¨mL´1 for CVD monitoring) could be distinguished from each other and from the
unreacted particles. Furthermore, negative controls were performed to ensure that unspecific binding
of reagents to the particles did not occur. Here, streptavidin-coated magnetic particles, having not
undergone the 1˝ anti-CRP functionalisation step, were trapped in the capillary and flushed with
CRP (10 µg¨mL´1) and 2˝ anti-CRP-FITC (100 µg¨mL´1). Image analysis showed no increase in
fluorescence that confirmed a lack of unspecific binding, as previously demonstrated [69,70].
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Figure 7. Results obtained via a magnetic particle plug-based sandwich assay for C-reactive
protein (CRP). (a) Fluorescence image of a particle plug prior to the CRP assay, demonstrating the
auto-fluorescence of the polystyrene-based particles. Magnetic particles were functionalised with
primary CRP antibodies (1˝ anti-CRP). (b) Fluorescence exhibited by a particle plug after exposure
to 1 µg¨mL´1 CRP and subsequent labelling with fluorescently tagged secondary CRP antibody
(2˝ anti-CRP-FITC; 100 µg¨mL´1); and (c) after exposure to 10 µg¨mL´1 CRP and labelling with 2˝
anti-CRP-FITC (100 µg¨mL´1). (d) Plot of fluorescence intensities of the particle plugs at varying
concentrations of RP.
These results demonstrated the ability to perform two-step sandwich immunoassays for clinically
relevant biomarkers. Further investigation will be required to determine whether a suitable calibration
curve can be generated in the 1–10 µg¨mL´1 region for hs-CRP testing, but its use for the determination
of inflammation and infection, requiring less sensitivity, appears easily achievable. The 3 min analyte
capture (CRP) and labelling (2˝ anti-CRP-FITC) steps at 300 µL¨h´1 resulted in the consumption of
15 µL of both the sample and the relatively expensive labelling reagent. While already a low volume
of each, this could be further reduced by optimising the reaction times. Furthermore, the total time
of the magnetic plug-based was <15 min; far faster compared to conventional off-chip magnetic
particle-based assays (50 min) and traditional ELISA testing (80 min) [69]. Future work will involve
generation of a full calibration range for both conventional CRP and hs-CRP concentration ranges, and
the analysis of real serum samples.
3.4. Progesterone (P4) Assay
Having established that the magnetic particle plug-based platform could be used for sandwich
ELISAs, we next investigated the potential of the system towards achieving competitive ELISAs of
clinically relevant biomarkers. Initial tests for this involved the detection of fluorescently labelled
progesterone (P4-FITC). Progesterone (P4) is a steroid hormone that plays an important role in the
menstrual cycle and pregnancy, being secreted to help prepare the uterus for pregnancy and, following
conception, to ensure development of the embryo [79–82]. Thus, the monitoring of P4 can be used to
determine the time at which fertility is highest, for the diagnosis of early pregnancy, to check for the risk
or occurrence of miscarriage, and for the detection of adrenal or ovarian cancer. Levels of progesterone
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are typically less than 1 ng¨mL-1 pre-ovulation, increasing to 5–20 ng¨mL-1 mid-menstruation cycle,
11.2–90.0 ng¨mL-1 in the 1st trimester of pregnancy, 25.6–89.4 ng¨mL-1 in the 2nd trimester, and 48–150
to ě300 ng¨mL´1 in the 3rd trimester [82], with levels being present up to a maximum of 1 g¨mL´1 in
serum [83].
Preliminary tests were performed on the magnetic plug platform by first introducing anti-P4
functionalised magnetic particles (1 ˆ 107 particles¨mL´1) into the capillary at 300 L¨h´1 for 2 min
to form the plug, before flushing the plug with P4-FITC for 3 min, and finally washing the plug
for 3 min with PBS solution. A range of P4-FITC concentrations were tested, from 0.1–100 g¨mL´1,
and the fluorescence intensity of the particle plug was measured at each concentration. Due to
the proof-of-principle nature of this study, the levels of P4 tested covered the upper end of the P4
concentration range typically found during the 3rd trimester and the maximum level found in blood
(1 g¨mL´1). Figure 8a–e shows fluorescence images at each of the concentrations. The fluorescence
signals measured at each P4-FITC concentration are shown in Figure S2 in the Supplementary Material,
demonstrating a typical dose–response curve with an initially rapid increase in signal intensity as
the concentration increased, before reaching a plateau as the number of active sites on the magnetic
particles was diminished. Plotting the fluorescence intensity against the logarithm of the P4-FITC
concentration (background corrected) yielded a linear response over this wide calibration range
(Figure 8f). However, the standard deviations of the results were quite large in this case, which
may have been caused in part by the relatively low magnification employed for image capture
(see the photographs in Figure 8), which would affect the signal intensity. This could be addressed by
capturing images of the particle plugs at a higher magnification or by employing a different detection
technique. Negative controls were also performed by flushing P4-FITC over a plug of carboxylic acid
functionalised particles (i.e., particles which had not had anti-P4 conjugated to them) for 1 h, which
thereafter exhibited no fluorescence and so confirmed no issues with unspecific binding.Micromachines 2016, 7, 77 12 of 17 
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These preliminary studies show the feasibility of performing competitive ELISAs for biomarkers,
such as progesterone hormone, in 10 min and using only 10 µL of sample, though clearly further
work is required in order to develop the method into a viable platform for clinical hormone analysis.
The next steps towards this goal will be the introduction of unlabelled P4 at varying concentrations
alongside the P4-FITC in order to perform actual competitive assays, while the limit of detection
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and linear range will be explored at the more clinically relevant levels of 1 ng¨mL´1 to 1 µg¨mL´1.
This would then lead to the testing of real serum samples.
4. Outlook
We have performed preliminary studies to establish the feasibility of applying the magnetic
particle plug-based platform for clinically relevant bioassays. Characterisation of particle plug
formation was performed in order to generate large particle plugs in a short timeframe, and three types
of assay systems were investigated: streptavidin-biotin binding assays for evaluation of the platform for
quantitative assays, C-reactive protein (CRP) assays for testing the ability to perform sandwich ELISAs
of a biomarker in a clinically relevant concentration range, and fluorescently-labelled progesterone
(P4-FITC) assays with a view to competitive ELISAs for hormone analysis. While optimisation is
still required, these tests show great promise for quantitative analysis of a variety of biomarkers.
In particular, the CRP assay, which can already be applied in a relevant concentration range, requires
only a full calibration curve to be generated prior to analysis of real samples. The P4 analysis requires
more work; while the assay mechanism operates as required and differences in concentration can be
detected using the relatively high concentrations tested, the limits of detection need to be established
and a calibration curve generated using fluorescently labelled and unlabelled P4 in a clinically relevant
range before real serum analysis will be possible. In the case of both analyses, however, testing of
robustness of the platform will also be required, including tests of inter-day and inter-chip variability.
The magnetic particle plug-based platform represents an extremely simple setup, requiring only a
capillary, two NdFeB magnets, a syringe pump, and a detection system. It also brings several other
advantages such as the speed with which assays can be performed. Each step of the process (particle
loading, reagent addition, washing) took only 2–3 min each, meaning that total times for each assay
was <15 min. Using other methods of performing CRP assays for comparison [69], typical ELISAs will
take ~80 min and off-chip magnetic particle-based assays require ~50 min due to the multiple manual
reaction and washing steps that are both time-consuming and labour-intensive. Hence, the on-chip
platform here represents a far faster approach, while typically using only 15 µL of sample and 15 µL of
the expensive labelling reagents compared to the hundreds of microliters of reagents used in ELISA
and conventional magnetic particle assays (although ELISA only requires 5 µL of sample). However,
further optimisation of reagent and washing times could lead to further reductions in time frames for
the magnetic particle plug-based assays, which would in turn result in the use of lower volumes of
samples and reagents.
Integrated microelectromagnets could potentially be employed as part of the system to enable
finer control of the magnetic field and the ability to switch the field on-and-off as required, as has been
demonstrated previously [33–38]. However, adding such components would increase the complexity
of the setup; an aspect we are trying to avoid in our goal of developing a very simple, robust,
user-friendly platform.
While the amount of time allowed for the reaction and washing steps is one method of reducing
overall time frames, another would be to decrease the time required to switch between the different
solutions (magnetic particle suspension, reagent solutions, washing buffer) being introduced into the
microchannel. In the current system, the syringe pump was paused and the flow allowed to come
to a stop before manually moving the inlet tubing from one sample or buffer reservoir to the next,
with care taken not to allow introduction of air into the capillary during the exchange. These steps
could be made far faster, and without the worry of introducing air bubbles, by employing a multi-port
valve that allows simultaneous connection of each reservoir to the inlet tubing (e.g., the V-240 6-Way
Selection Valve from IDEX Health & Science [84]). Alternatively, a moving array of microvial reservoirs
at the capillary inlet could be employed, as has been successfully implemented for sample introduction
in microfluidic capillary electrophoresis [85]. In addition, by writing a simple program for controlling
such a valve or microarray system and the syringe pump, it would be very easy to automate the
various steps of the assays. This would also help to enable multiplexed assays by easily allowing the
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generation of multiple particle plugs having different surface functionalities for various analytes, as
we have demonstrated previously [50,68].
Furthermore, while current detection was achieved using a standard fluorescence microscope,
which brings with it an associated bulk and expense, recent advances in miniaturised fluorescence
detection systems could conceivably be applied to this platform to yield a far more compact and
portable system [86–88]. While fluorescence detection was employed in the experiments described
here, this could be replaced with a chemiluminescence setup by exchanging the fluorescent tags on the
antibodies/antigens for a suitable enzyme, e.g., horseradish peroxidase (HRP), and the washing of the
particle plug with a solution of a chemiluminescent substrate solution. This would also reduce the
detection setup to a photomultiplier tube (PMT) without the need for a light source.
Clearly, there are a number of steps to be completed before a true analysis platform can be
established, and the improvements suggested above would enable a faster, more sensitive, and more
compact assay system that uses only small volumes of samples and reagents while requiring minimal
manual steps. However, this represents a longer-term vision for the system. Nonetheless, the results
described here have demonstrated the use of the miniaturised magnetic particle plug-based assay
platform for the detection of several analytes at varying concentrations, showing great potential for fast,
low volume sandwich ELISAs and competitive ELISAs for a range of clinically relevant biomarkers.
5. Conclusions
We have demonstrated a fast, low volume assay platform in which functionalised magnetic
particles are introduced into a microchannel and trapped as a plug between two permanent magnets,
allowing their subsequent exposure to consecutive reagent and washing solutions, followed by
fluorescence analysis of the particle plug. The formation of the particle plug was characterised
and the ability to perform quantitative analysis determined using a streptavidin-biotin binding assay
(LOD = 40 ng¨mL´1). The capacity to detect clinically relevant biomarkers was explored using
the inflammation marker, C-reactive protein (CRP), in a sandwich assay, and the steroid hormone,
progesterone (P4), in a binding assay with a view to competitive ELISAs. Assays were achieved in
less than 15 min, a significant reduction in time compared to conventional procedures, and used
only 10–15 µL each of samples and reagents. This shows the potential of the platform for the rapid
detection of a range of biomarkers, and future work will involve further optimisation of the setup and
the procedure for the analysis of real samples.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-666X/7/5/77/s1,
Figure S1: Optimisation of CCD camera exposure time. The fluorescence intensity of streptavidin functionalised
particle plugs is plotted against the concentration of fluorescently labelled biotin at different CCD exposure times
(0.1–0.6 s): (a) biotin concentrations of 0.1–5 µg¨mL´1, demonstrating a typical dose-response curve; and (b) linear
range plotted for 0.1–2 g¨mL´1 biotin concentration, Figure S2: Fluorescently labelled progesterone (P4-FITC)
assay. Magnetic particles functionalised with anti-P4 were exposed to different concentrations of P4-FITC and the
resultant fluorescence intensities were measured. The plot follows a typical dose–response curve.
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